

CLAIMS

1. Use of an anti-CD38 antibody for the manufacture of a medicament for the treatment of multiple myeloma, wherein the medicament is for administration to an individual in combination with an Interleukin-2 analog (IL-2 analog), wherein the medicament is for administration on Days 1, 8, 15, and 22 of a first 28-day cycle and then administration on Days 1 and 15 of a 28-day cycle for at least one additional cycle and
wherein the IL-2 analog is for administration once every two weeks or once every three weeks.
2. The use according to claim 1, wherein the anti-CD38 antibody is isatuximab and the medicament is for intravenous administration at a dose of 10 mg/kg.
3. The use according to claim 1, wherein the CD-38 antibody is isatuximab and the medicament is for subcutaneous administration at a dose of 1400 mg.
4. The use according to any one of claims 1-3, wherein the IL-2 analog comprises a non-natural amino acid, *N*6-((2-azidoethoxy)-carbonyl)-L-lysine (AzK), and wherein the AzK is pegylated.
5. The use according to claim 1, wherein the IL-2 analog is for administration at a dose of 16 ug/kg, 24 ug/kg, or 32 ug/kg.
6. The use according to any one of claims 1-3, and 5, wherein the medicament is for administration on Days 1 and 15 of a 28-day cycle for at least 11 cycles and then for administration on Day 1 of a 28-day cycle for one or more additional cycles.
7. The use according to any one of claims 1-3, and 5, wherein the individual received one or more lines of therapy for the treatment of multiple myeloma prior to receiving the first cycle of treatment, wherein the one or more prior lines of therapy include an anti-CD38 medication and an anti-BCMA medication.
8. Use of an anti-CD38 antibody for the manufacture of a medicament for the treatment of multiple myeloma, wherein the medicament is for administration to an individual

in combination with an Interleukin-2 analog (IL-2 analog),

wherein the anti-CD38 antibody is isatuximab and wherein the IL-2 analog comprises a non-natural amino acid, *N*6-((2-azidoethoxy)-carbonyl)-L-lysine (AzK), wherein the AzK is pegylated,

wherein the isatuximab is for administration on Days 1, 8, 15, and 22 of a first 28-day cycle and then for administration on Days 1 and 15 of a 28-day cycle for at least one additional cycle,

wherein the isatuximab is for intravenous administration at a dose of 10 mg/kg or is for subcutaneous administration at a dose of 1400 mg,

wherein the IL-2 analog is for administration to the individual once every two weeks or once every three weeks, at a dose of 16 ug/kg, 24 ug/kg, or 32 ug/kg, and

wherein the individual received one or more lines of therapy for the treatment of multiple myeloma prior to receiving the first cycle of treatment, wherein the one or more prior lines of therapy include an anti-CD38 medication and an anti-BCMA medication.

9. The use according to any one of claims 1-3, 5, and 8, wherein Natural Killer (NK) cells having expression of CD38 reduced or knocked-out (NK-CD38KO cells) are also to be administered to the individual.

10. The use according to claim 9, wherein the NK cells were isolated from a human sample.